ESG Implemenation Consulting Services

AGP Wins Silver Award at the SAFA Best Presented Annual Report Awards 2024

AGP Wins 1st Position in Pharmaceutical Category at BCSR Awards 2024 — for the Second Consecutive Year!

AGP Celebrates Dual Recognition at the 8th Pakistan Pharma Summit & PESA Awards 2025

AGP Receives the 22nd Annual Environment Excellence Award 2025

AGP Wins GDEIB Awards in Nine Categories

AGP x TrashIt Sustainability Training

AGP x Cyber Security Awareness Training

AGP x Cancer Foundation Hospital: Breast Cancer Awareness Session

AGP Visits Karachi Down Syndrome Program (KDSP)

Diwali Celebration at AGP: Honoring Diversity, Culture & Togetherness

AGP Limited Secures 1st Position at BCSR Awards 2023

AGP collaborates with Childlife Foundation on Children’s Day 2023

AGP Launched Peridots – A Thanda Solution to Acidity, Gas and Indigestion

AGP secures 2nd Position at BCR Awards 2022

AGP wins Top Exporter Award at 6th PPMA Summit

AGP sponsors KDSP Carnival 2023

AGP bags big win at GDEIB Awards 2023

AGP continues partnership with IBA

AGP continues collaboration with TCF

AGP joins hands with SKMF

AGP continues partnership with ACF

AGP conducts Allergy Awareness Session At Pak Turk Maarif

Gong-Ringing Ceremony of AGP at PSX

Product List

Brivazen

Generic:
Brivaracetam

Therapeutic Class:
Antiepileptics

Composition:

  • Brivazen 25 mg Film-Coated Tablet:
    Each film-coated tablet contains Brivaracetam 25 mg.
  • Brivazen 50 mg Film-Coated Tablet:
    Each film-coated tablet contains Brivaracetam 50 mg.
  • Brivazen 100 mg Film-Coated Tablet:
    Each film-coated tablet contains Brivaracetam 100 mg.
  • Brivazen 10 mg/ml Oral Solution:
    Each ml of oral solution contains Brivaracetam 10 mg.

Description:
Brivazen (Brivaracetam) is an anticonvulsant or anti-seizure medication used to treat partial-onset (focal) seizures in epilepsy.

Indications:
Brivazen is indicated as adjunctive therapy in the treatment of partial-onset seizures, with or without secondary generalization, in adults, adolescents and children from 1 month of age with epilepsy.

Dosage:
The recommended dosage for adults, adolescents and children from 1 month of age is presented below.

Age and Body Weight Initial Dosage Minimum and Maximum Maintenance Dosage
Adults (16 years and older) 50 mg twice daily (100 mg per day) 25 mg to 100 mg twice daily
(50 mg to 200 mg per day)
Pediatric patients weighing 50 kg or more 25 mg to 50 mg twice daily
(50 mg to 100 mg per day)
25 mg to 100 mg twice daily
(50 mg to 200 mg per day)
Pediatric patients weighing 20 kg to less than 50 kg 0.5 mg/kg to 1 mg/kg twice daily
(1 mg/kg to 2 mg/kg per day)
0.5 mg/kg to 2 mg/kg twice daily
(1 mg/kg to 4 mg/kg per day)
Pediatric patients weighing 11 kg to less than 20 kg 0.5 mg/kg to 1.25 mg/kg twice daily
(1 mg/kg to 2.5 mg/kg per day)
0.5 mg/kg to 2.5 mg/kg twice daily
(1 mg/kg to 5 mg/kg per day)
Pediatric patients weighing  Less than 11 kg 0.75 mg/kg to 1.5 mg/kg twice daily
(1.5 mg/kg to 3 mg/kg per day)
0.75 mg/kg to 3 mg/kg twice daily
(1.5 mg/kg to 6 mg/kg per day)

Use in Adults:
The recommended starting dose is either 50 mg/day or 100 mg/day, based on the physician’s assessment of the required seizure reduction in relation to potential adverse reactions. Based on individual patient response and tolerability, the dose may be adjusted within the effective dose range of 50 mg/day to 200 mg/day.

Adolescents and children weighing ≥50 kg
The recommended starting dose is 50mg/day. Brivaracetam may alternatively be initiated at 100mg/day based on the physician’s assessment of the need for seizure control. The recommended maintenance dose is 100 mg/day. Based on individual patient response, the dose may be adjusted within the effective dose range of 50 mg/day to 200 mg/day.

Use in Children:
Adolescents and children weighing ≥20 kg to <50 kg
The recommended starting dose is 1mg/kg/day. Brivaracetam may alternatively be initiated at doses up to 2mg/kg/day based on the physician’s assessment of the need for seizure control. The recommended maintenance dose is 2mg/kg/day. Based on individual patient response, the dose may be adjusted within the effective dose range of 1mg/kg/day to 4mg/kg/day.

Children weighing ≥10 kg to <20 kg
The recommended starting dose is 1 mg/kg/day. Brivaracetam may alternatively be initiated at doses up to 2.5mg/kg/day based on the physician’s assessment of the need for seizure control. The recommended maintenance dose is 2.5 mg/kg/day. Based on individual patient response, the dose may be adjusted within the effective dose range of 1mg/kg/day to 5 mg/kg/day.

Children weighing <11 kg
The recommended starting dose is 1.5 mg/kg/day. Brivaracetam may alternatively be initiated at doses up to 3mg/kg/day based on the physician’s assessment of the need for seizure control.

Presentations:

  • Brivazen 25 mg, 50 mg and 100 mg film-coated tablets are available in packs of 14 tablets each.
  • Brivazen Oral Solution 10 mg/ml is available in a 60 ml bottle.